Search

Your search keyword '"Conroy T"' showing total 846 results
Start Over Author "Conroy T"
846 results on '"Conroy T"'

53. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel†

Author

Van Laethem, J.-L., Verslype, C., Iovanna, J. L., Michl, P., Conroy, T., Louvet, C., Hammel, P., Mitry, E., Ducreux, M., Maraculla, T., Uhl, W., Van Tienhoven, G., Bachet, J. B., Maréchal, R., Hendlisz, A., Bali, M., Demetter, P., Ulrich, F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J. P., and Lutz, M.

Published
2012
Full Text
View/download PDF

54. 422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs)

Author

Fontana, E., primary, Zichi, C., additional, Smyth, E.C., additional, Mauer, M., additional, Rödel, C., additional, Fokas, E., additional, Hofheinz, R.D., additional, Arnold, D., additional, Schmoll, H.J.E-V., additional, Van Cutsem, E., additional, Haustermans, K.M., additional, Stein, A., additional, Gérard, J-P., additional, Conroy, T., additional, Jouffroy, C., additional, Moehler, M., additional, Lordick, F., additional, Ben-Aharon, I., additional, and Di Maio, M., additional

Published
2020
Full Text
View/download PDF

55. LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial

Author

Borg, C., primary, Rullier, E., additional, Marchal, F., additional, Etienne, P-L., additional, Rio, E., additional, Francois, E., additional, Mesgouez-Nebout, N., additional, Vendrely, V., additional, Artignan, X., additional, Bouche, O., additional, Gargot, D., additional, Boige, V., additional, Bonichon-Lamichhane, N., additional, Louvet, C., additional, Morand, C., additional, de la Fouchardiere, C., additional, Juzyna, B., additional, Mollevi, C., additional, Castan, F., additional, and Conroy, T., additional

Published
2020
Full Text
View/download PDF

59. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45

Author

Bjelic-Radisic, V., primary, Cardoso, F., additional, Cameron, D., additional, Brain, E., additional, Kuljanic, K., additional, da Costa, R.A., additional, Conroy, T., additional, Inwald, E.C., additional, Serpentini, S., additional, Pinto, M., additional, Weis, J., additional, Morag, O., additional, Lindviksmoen Astrup, G., additional, Tomaszweksi, K.A., additional, Pogoda, K., additional, Sinai, P., additional, Sprangers, M., additional, Aaronson, N., additional, Velikova, G., additional, Greimel, E., additional, Arraras, J., additional, Bottomley, A., additional, Bleiker, Eveline, additional, Bliem, Brigitte, additional, Chie, Weichu, additional, Creutzberg, Carien, additional, Deville, Valerie, additional, Duhoux, Francois, additional, Eilf, Kirsten, additional, Hartup, Sue, additional, Koller, Michael, additional, Nagele, Eva, additional, Nicolatou-Galitis, Ourania, additional, Oberguggenberger, Anne, additional, Schmalz, Claudia, additional, and Winters, Zoe, additional

Published
2020
Full Text
View/download PDF

64. 1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial

Author

Nicolle, R., Bachet, J-B., Harlé, A., Iovanna, J.L., Hammel, P., Rebours, V., Turpin, A., Ben Abdelghani, M., A. wei, Mitry, E., Lopez, A., Biagi, J., Francois, E., Artru, P., Lambert, A., Renouf, D.J., Mauduit, M., Dussetti, N., Conroy, T., and Cros, J.

Published
2022
Full Text
View/download PDF

65. Speaking Up for Fundamental Care: the ILC Aalborg Statement

Author

Kitson, A., Carr, D., Conroy, T., Feo, R., Gronkjaer, M., Huisman-de Waal, G.J., Jackson, D., Jeffs, L., Merkley, J., Athlin, A. Muntlin, Parr, J., Richards, D.A., Sorensen, E.E., Wengstrom, Y., Kitson, A., Carr, D., Conroy, T., Feo, R., Gronkjaer, M., Huisman-de Waal, G.J., Jackson, D., Jeffs, L., Merkley, J., Athlin, A. Muntlin, Parr, J., Richards, D.A., Sorensen, E.E., and Wengstrom, Y.

Abstract

Contains fulltext : 215530.pdf (publisher's version ) (Open Access), OBJECTIVE: The International Learning Collaborative (ILC) is an organisation dedicated to understanding why fundamental care, the care required by all patients regardless of clinical condition, fails to be provided in healthcare systems globally. At its 11th annual meeting in 2019, nursing leaders from 11 countries, together with patient representatives, confirmed that patients' fundamental care needs are still being ignored and nurses are still afraid to 'speak up' when these care failures occur. While the ILC's efforts over the past decade have led to increased recognition of the importance of fundamental care, it is not enough. To generate practical, sustainable solutions, we need to substantially rethink fundamental care and its contribution to patient outcomes and experiences, staff well-being, safety and quality, and the economic viability of healthcare systems. KEY ARGUMENTS: We present five propositions for radically transforming fundamental care delivery:Value: fundamental care must be foundational to all caring activities, systems and institutionsTalk: fundamental care must be explicitly articulated in all caring activities, systems and institutions.Do: fundamental care must be explicitly actioned and evaluated in all caring activities, systems and institutions.Own: fundamental care must be owned by each individual who delivers care, works in a system that is responsible for care or works in an institution whose mission is to deliver care. RESEARCH: fundamental care must undergo systematic and high-quality investigations to generate the evidence needed to inform care practices and shape health systems and education curricula. CONCLUSION: For radical transformation within health systems globally, we must move beyond nursing and ensure all members of the healthcare team-educators, students, consumers, clinicians, leaders, researchers, policy-makers and politicians-value, talk, do, own and research fundamental care. It is only through coordinated, collaborati

Published
2019

66. Speaking Up for Fundamental Care: the ILC Aalborg Statement.

Author

Kitson, A, Carr, D, Conroy, T, Feo, R, Grønkjær, M, Huisman-de Waal, G, Jackson, D, Jeffs, L, Merkley, J, Muntlin Athlin, Å, Parr, J, Richards, DA, Sørensen, EE, Wengström, Y, Kitson, A, Carr, D, Conroy, T, Feo, R, Grønkjær, M, Huisman-de Waal, G, Jackson, D, Jeffs, L, Merkley, J, Muntlin Athlin, Å, Parr, J, Richards, DA, Sørensen, EE, and Wengström, Y

Abstract

OBJECTIVE: The International Learning Collaborative (ILC) is an organisation dedicated to understanding why fundamental care, the care required by all patients regardless of clinical condition, fails to be provided in healthcare systems globally. At its 11th annual meeting in 2019, nursing leaders from 11 countries, together with patient representatives, confirmed that patients' fundamental care needs are still being ignored and nurses are still afraid to 'speak up' when these care failures occur. While the ILC's efforts over the past decade have led to increased recognition of the importance of fundamental care, it is not enough. To generate practical, sustainable solutions, we need to substantially rethink fundamental care and its contribution to patient outcomes and experiences, staff well-being, safety and quality, and the economic viability of healthcare systems. KEY ARGUMENTS: We present five propositions for radically transforming fundamental care delivery:Value: fundamental care must be foundational to all caring activities, systems and institutionsTalk: fundamental care must be explicitly articulated in all caring activities, systems and institutions.Do: fundamental care must be explicitly actioned and evaluated in all caring activities, systems and institutions.Own: fundamental care must be owned by each individual who delivers care, works in a system that is responsible for care or works in an institution whose mission is to deliver care. RESEARCH: fundamental care must undergo systematic and high-quality investigations to generate the evidence needed to inform care practices and shape health systems and education curricula. CONCLUSION: For radical transformation within health systems globally, we must move beyond nursing and ensure all members of the healthcare team-educators, students, consumers, clinicians, leaders, researchers, policy-makers and politicians-value, talk, do, own and research fundamental care. It is only through coordinated, collaborati

Published
2019

82. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire

Author

Petersen, M.A., Aaronson, N.K., Arraras, J.I., Chie, W.C., Conroy, T., Costantini, A., Dirven, L., Fayers, P., Gamper, E.M., Giesinger, J.M., Habets, E.J.J., Hammerlid, E., Helbostad, J., Hjermstad, M.J., Holzner, B., Johnson, C., Kemmler, G., King, M.T., Kaasa, S., Loge, J.H., Reijneveld, J.C., Singer, S., Taphoorn, M.J.B., Thamsborg, L.H., Tomaszewski, K.A., Velikova, G., Verdonck-de Leeuw, I.M., Young, T., Groenvold, M., European Org Res Treatment Cancer, Neurology, Otolaryngology / Head & Neck Surgery, APH - Mental Health, and APH - Personalized Medicine

Subjects
Male, Cancer Research, medicine.medical_specialty, Psychometrics, Health Status, Item banking, Item bank, Taiwan, Sample (statistics), Item response theory, Statistical power, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Cost of Illness, Software Design, Neoplasms, Activities of Daily Living, medicine, Health Status Indicators, Humans, Medical physics, Health related quality of life, 030212 general & internal medicine, Patient Reported Outcome Measures, Patient-reported outcome, Item development, Comparability, EORTC QLQ-C30, Middle Aged, humanities, 3. Good health, Europe, Computerized adaptive test, Oncology, Sample size determination, 030220 oncology & carcinogenesis, Quality of Life, Female, Psychology
Abstract

Background To optimise measurement precision, relevance to patients and flexibility, patient-reported outcome measures (PROMs) should ideally be adapted to the individual patient/study while retaining direct comparability of scores across patients/studies. This is achievable using item banks and computerised adaptive tests (CATs). The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) is one of the most widely used PROMs in cancer research and clinical practice. Here we provide an overview of the research program to develop CAT versions of the QLQ-C30's 14 functional and symptom domains. Methods The EORTC Quality of Life Group's strategy for developing CAT item banks consists of: literature search to identify potential candidate items; formulation of new items compatible with the QLQ-C30 item style; expert evaluations and patient interviews; field-testing and psychometric analyses, including factor analysis, item response theory calibration and simulation of measurement properties. In addition, software for setting up, running and scoring CAT has been developed. Results Across eight rounds of data collections, 9782 patients were recruited from 12 countries for the field-testing. The four phases of development resulted in a total of 260 unique items across the 14 domains. Each item bank consists of 7–34 items. Psychometric evaluations indicated higher measurement precision and increased statistical power of the CAT measures compared to the QLQ-C30 scales. Using CAT, sample size requirements may be reduced by approximately 20–35% on average without loss of power. Conclusions The EORTC CAT Core represents a more precise, powerful and flexible measurement system than the QLQ-C30. It is currently being validated in a large independent, international sample of cancer patients. © 2018. This is the authors’ accepted and refereed manuscript to the article. Locked until 21..2019 due to copyright restrictions. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

Published
2018

86. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)

Author

Adenis, A., primary, Bennouna, J., additional, Etienne, P.L., additional, Bogart, E., additional, Francois, E., additional, Galais, M.P., additional, Ben Abdelghani, M., additional, Michel, P., additional, Metges, J.P., additional, Dahan, L., additional, Conroy, T., additional, Ghiringhelli, F., additional, Drouillard, A., additional, El Hajbi, F., additional, Samalin, E., additional, Hiret, S., additional, Delaine-Clisant, S., additional, Mariette, C., additional, Penel, N., additional, Piessen, G., additional, and Le Deley, M.C., additional

Published
2019
Full Text
View/download PDF

87. Abstract P1-12-01: Withdrawn

Author

Bjelic-Radisic, V, primary, Bottomley, A, additional, Cardoso, F, additional, Cameron, D, additional, Brain, E, additional, Kuljanic, K, additional, de Costa, RA, additional, Conroy, T, additional, Deville, V, additional, Inwald, E, additional, Serpentini, S, additional, Pinto, M, additional, Bleiker, E, additional, Arrares, J, additional, Duhoux, F, additional, Weiss, J, additional, Morag, O, additional, Lindviksmoen Astrup, G, additional, Tomaszweksi, K, additional, Velikova, G, additional, Pogoda, K, additional, Nagele, E, additional, Bliem, B, additional, Sinai, P, additional, Sprangers, M, additional, Aaronson, N, additional, and Greimel, E, additional

Published
2019
Full Text
View/download PDF

92. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45

Author

Bjelic-Radisic, V., primary, Bottomley, A., additional, Cardoso, F., additional, Cameron, D., additional, Brain, E., additional, Kuljanic, K., additional, de Costa, R.A., additional, Conroy, T., additional, Inwald, E., additional, Serpentini, S., additional, Pinto, M., additional, Weis, J., additional, Morag, O., additional, Guro Lindviksmoen Astrup, G., additional, Tomaszweksi, K., additional, Pogoda, K., additional, Sinai, P., additional, Sprangers, M.A.G., additional, Aaronson, N., additional, and Greimel, E., additional

Published
2018
Full Text
View/download PDF

98. COnsensus statement on Mandatory Measurements in PAncreatic Cancer Trials for systemic treatment of unresectable disease (COMMPACT)

Author

van Rijssen, L. B., ter Veer, E., Besselink, M. G., Mali, R. M. A., Berlin, J., Boeck, S., Bonnetain, F., Conroy, T., Deplanque, G., Goldstein, D., Glimelius, Bengt, Neoptolemos, J. P., Reni, M., Scheithauer, W., van der Meer, J., Wilmink, J. W., van der Poel, M. J., Busch, O. R., van Oijen, M. G. H., van Laarhoven, H. W. M., van Rijssen, L. B., ter Veer, E., Besselink, M. G., Mali, R. M. A., Berlin, J., Boeck, S., Bonnetain, F., Conroy, T., Deplanque, G., Goldstein, D., Glimelius, Bengt, Neoptolemos, J. P., Reni, M., Scheithauer, W., van der Meer, J., Wilmink, J. W., van der Poel, M. J., Busch, O. R., van Oijen, M. G. H., and van Laarhoven, H. W. M.

Published
2017

99. Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283–288

Author

Bjelic-Radisic, V., Cardoso, F., Cameron, D., Brain, E., Kuljanic, K., da Costa, R.A., Conroy, T., Inwald, E.C., Serpentini, S., Pinto, M., Weis, J., Morag, O., Lindviksmoen Astrup, G., Tomaszewski, K.A., Pogoda, K., Sinai, P., Sprangers, M., Aaronson, N., Velikova, G., Greimel, E., Arraras, J., and Bottomley, A.

Published
2020
Full Text
View/download PDF

100. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Author

Nordlinger, B, Sorbye, H, Glimelius, B, Poston, Gj, Schlag, Pm, Rougier, P, Bechstein, Wo, Primrose, Jn, Walpole, Et, FINCH JONES, M, Jaeck, D, Mirza, D, Parks, Rw, Collette, L, Praet, M, Bethe, U, VAN CUTSEM, E, Scheithauer, W, Gruenberger, T, Hohenberger, W, Iveson, T, Karner, J, Levi, J, Hugh, T, DE GREVE, J, Chan, A, Davidson, B, Lindner, P, Peeters, M, Stein, B, Diamond, T, Ducreux, M, Lasser, P, Graeven, U, Paillot, B, Doran, J, Gouillat, C, Iesalnieks, I, Jauch, Kw, JAGOT LACOUSSIERE, P, Jansen, Rl, Koehne, H, Konopke, R, Otto, F, Sherlock, D, VAN HAZEL, G, Ackland, S, Bedenne, L, Bories, E, CLAVERO FABRI MC, Conroy, T, KAMINSKY FORRETT MC, Husseini, F, Karapetis, C, Mãœller, L, Price, T, Rosenberg, R, Schott, J, Tschmelitsch, J, VAN LAETHEM JL, Wals, J, Weimann, A, Arnaud, Jp, Arsene, D, Auby, D, Bhattacharya, S, Cebon, E, Cherqui, D, Confente, C, Dousset, B, Frickhofen, N, Frilling, A, Evan, P, Ganju, V, Hã–ffken, K, Lazorthes, F, Letoublon, C, Madroszyk, A, Nitti, Donato, Orr, B, Pariente, Ea, Pector, Jc, Raoul, Jl, Rees, M, Ridwelski, K, Rouanet, P, Toogood, Gj, Vergauwe, P, Wilke, Hj, Kaplan, R, Horiot, Jc, Littbrand, B, Awada, A, Stenning, S, Lejeune, F., Haukeland University Hospital, University of Bergen (UiB), Uppsala Universitet [Uppsala], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Chirurgie Viscérale, Hépatique et de Transplantation Multiorganes, Université Louis Pasteur - Strasbourg I, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), University Hospitals Leuven [Leuven], Centre Énergétique et Procédés (CEP), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), and Université d'Angers (UA)

Subjects
Adult, Male, medicine.medical_specialty, Organoplatinum Compounds, Colorectal cancer, [SDV]Life Sciences [q-bio], 030230 surgery, Perioperative Care, 03 medical and health sciences, 0302 clinical medicine, Hepatic arterial infusion, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, business.industry, Liver Neoplasms, Hazard ratio, Cancer, General Medicine, Perioperative, Middle Aged, medicine.disease, Combined Modality Therapy, 3. Good health, Surgery, Oxaliplatin, Clinical trial, 030220 oncology & carcinogenesis, Female, Fluorouracil, Colorectal Neoplasms, Liver cancer, business, medicine.drug
Abstract

Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Methods This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0·71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479. Findings In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1–6) preoperative cycles and 115 (63%) patients received a median six (1–8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7·3% (from 28·1% [95·66% CI 21·3–35·5] to 35·4% [28·1–42·7]; HR 0·79 [0·62–1·02]; p=0·058) in randomised patients; 8·1% (from 28·1% [21·2–36·6] to 36·2% [28·7–43·8]; HR 0·77 [0·60–1·00]; p=0·041) in eligible patients; and 9·2% (from 33·2% [25·3–41·2] to 42·4% [34·0–50·5]; HR 0·73 [0·55–0·97]; p=0·025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0·04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group. Interpretation Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results